Japan· JP-2259714G2024
ウメクリジニウム臭化物
A umeclidinium bromide product containing ウメクリジニウム臭化物, registered in Japan by グラクソ・スミスクライン, on the national reimbursement list. The same ATC class is registered in 12 of our 19 countries.
Checked against MHLW / PMDA (Japan) on
Informational only — not a medical device.
Where it is registered
Umeclidinium bromide is registered in 12 of 19 countries.
Countries holding a registration under ATC R03BB07 (umeclidinium bromide), each read from that country’s own register.
- This record: Japan, from MHLW / PMDA (Japan)
- 7 of them publish a price we can compare per daily dose
Umeclidinium bromide · ATC R03BB07
12 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
Price per daily dose
What a daily dose of umeclidinium bromide costs, country by country.
Normalised to the WHO defined daily dose (55 mcg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Umeclidinium bromide · price per daily dose (55 mcg)
USD · FX 28 Sept 2026
- CH Switzerland$1.57
The record
At a glance
MHLW / PMDA (Japan)- Active substance
- ウメクリジニウム臭化物
- Manufacturer
- グラクソ・スミスクライン
- Country
- Japan (JP)
- ATC code
- R03BB07
- ATC class
- Umeclidinium bromide
- Defined daily dose
- 55 mcg, Inhal
- Reimbursed
- Yes
- Source register
- MHLW / PMDA (Japan)
- Last checked
- September 25, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
114 interactions on record for umeclidinium bromide.
Graded by severity as the source publishes them — 113 moderate. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Umeclidinium bromide · interactions on record
114 records
- 113 moderate
- 1 minor
Most severe, free to view
- DicycloverineA03AA07moderate
- PropanthelineA03AB05moderate
- MepenzolateA03AB12moderate
- TrospiumA03AB20moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under R03BB07
Umeclidinium bromide, as other registers publish it.
- SwitzerlandIncruse Ellipta
- FinlandIncruse ElliptaParanova Oy
- SwitzerlandIncruse Ellipta
- PolandIncruse ElliptaGlaxoSmithKline (Ireland) Limited
- IcelandIncruse ElliptaGlaxoSmithKline Trading Services Limited
- DenmarkIncruse ElliptaGlaxosmithkline Trading Services Limited
- FinlandIncruse ElliptaGlaxoSmithKline Trading Services Limited
- NorwayIncruse ElliptaGlaxoSmithKline Trading Services Limited
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of MHLW / PMDA (Japan). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/d078d23a-335a-47d4-bf1f-83044ad4ceaf GET /v1/drugs/d078d23a-335a-47d4-bf1f-83044ad4ceaf?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"spec": "30吸入1キット",
"marks": null,
"source": "mhlw",
"remarks": null,
"yj_code": "2259714G2024",
"category": "外用薬",
"price_yen": 3402.6,
"generic_name": "ウメクリジニウム臭化物",
"product_name_jp": null,
"therapeutic_class": "2259",
"transitional_expiry": null
}See everything about umeclidinium bromide.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.